Richard A. Furie, MD, from Northwell Health explains the planning and execution of clinical trials for lupus nephritis.

Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE). As Dr. Furie explains in this video, clinical trials for this condition are difficult to develop due to the large variance seen in this condition. 

Fortunately, some medications are in development and early results are promising. For example, Dr. Furie presented data from the NOBILITY study at the ACR Convergence Meeting on November 7, 2020 showing obinutuzumab to sustain a benefit in complete renal response over a two year period in patients with lupus nephritis. Obinutuzumab is an anti-D20 monoclonal antibody in development to treat lupus nephritis. A phase 3 study (the REGENCY study) is currently underway for this drug. 

For more information about this and other auto-immune diseases, go to